Welcome to the Rosen Laboratory Website!

LAB NEWS

February 17, 2017

Ozanimod, discovered in the Rosen and Roberts laboratories, successfully treats Relapsing and Remitting Multiple Sclerosis in a 1346 patient phase 3 clinical trial. This disease-modifying treatment for MS was discovered in the Scripps Research Institute Molecular Libraries Screening Center, funded by the NIH Common Fund grant #5U54 MH084512 to Hugh Rosen.

Read the press release by clicking here

August 29, 2016

The Rosen Lab's S1P₃ mCherry mice are now being provided by The Jackson Laboratory, Catalog #028624. Click link for purchasing information: https://www.jax.org/strain/028624

February 16, 2016

Science Signaling:Editor's Choice review of our recent PNAS publication:

J. R. Teijaro, S. Studer, N. Leaf, W. B. Kiosses, N. Nguyen, K. Matsuki, H. Negishi, T. Taniguchi, M. B. A. Oldstone, H. Rosen, S1PR1-mediated IFNAR1 degradation modulates plasmacytoid dendritic cell interferon-α autoamplification. Proc. Natl. Acad. Sci. U.S.A. 113, 1351–1356 (2016).

CLICK HERE TO READ

February 12, 2016

Bench-to-bedside in multiple sclerosis

Brilliant results for MS Patients! TSRI compound to be presented at ACTRIMS 2016 Forum, February 18-20th. After 72 weeks, 92% of patients remained on Ozanimod. Efficacy was outstanding with 63% of 1mg patients and 44% of 0.5mg patients showing No Evidence of Disease Activity.

CLICK HERE TO SEE THE ABSTRACT OF THE DISCUSSION

January 24, 2016 - LAB IN THE NEWS

More uses for MS drug, TSRI study suggests: Ozanimod, discovered at TSRI, may help with other autoimmune diseases CLICK HERE TO GO TO THE ARTICLE

January 22, 2016 - NEW PUBLICATION

Teijaro JR, Studer S, Leaf N, Kiosses WB, Nguyen N, Matsuki K, Negishi H, Taniguchi T, Oldstone MB, Rosen H. (2016) S1PR1-mediated IFNAR1 degradation modulates plasmacytoid dendritic cell interferon-α autoamplification. Proc Natl Acad Sci USA. 2016 Jan 19. pii: 201525356. [Epub ahead of print] PMID: 26787880 CLICK HERE TO READ IT NOW

January 20, 2016 - LAB IN THE NEWS

Fierce Biotech Research - Scripps team spots a new mechanism that drives Celgene's ozanimod, potential rivals CLICK HERE TO GO TO THE ARTICLE

Additional Information on Ozanimod (RPC1063)

The Molecular Libraries and Imaging Program Continues to Pay Dividends

After Leaving the Common Fund

The Common Fund’s Molecular Libraries and Imaging (MLI) Program has made promising inroads in the development of new therapeutics for human disease. A compound initially discovered by the NIH Molecular Libraries Probe Production Center at The Scripps Research Institute (TSRI), which was a part of the MLI program, was a precursor to the drug candidate ozanimod; which is currently in two Phase III clinical trials –one for patients with relapsing multiple sclerosis and the other in patients with ulcerative colitis. Dr. Hugh Rosen, a professor at TSRI was a Center Principal Investigator...CLICK HERE TO READ ON

Receptos Reports Positive Phase 2 Results for RPC1063 in Relapsing Multiple Sclerosis

Read the RPC1063 abstract by clicking here

MLPCN Link

Comprehensive Center for Chemical Probe Discovery and Optimization at TSRI